Welcome to the IPE Reference Hub. This site uses cookies. Read our policy.

Federated Hermes

2020 Top 500 ranking: 36

Antimicrobial resistance and the challenge for pharmaceutical companies

Antimicrobial resistance and the challenge for pharmaceutical companies

A lack of research and development into new antibiotic classes compounds the serious threat that antimicrobial resistance poses to public health. In the fifth article in our pandemic series, Kimberley Lewis explores the role of pharmaceutical companies and how we engage on this key topic.

Federated Hermes 

This is premium content

You are not logged in, Sign in or register to request access. 
Please note: If you had prior access to this content you may need to sign in again.

Asset Owners

If you are an institutional investor you are eligable for free access to all premium content.

REGISTER NOW

Asset Managers

Asset managers with enhanced profiles are eligable for full access.

Please sign-in using your work email address or:

REGISTER NOW

 

Premium subscription 

Investment services

Non-asset management investment service providers are able to purchase a subscription for access to premium content such as:

  • Latest industry thought leadership, news and research from the managers
  • Ranking of the Top 400 asset managers and country and asset class surveys
  • Research and asset class or investment theme

Get access to premium content subscribe today